PI3K Inhibitors for HR+ Metastatic Breast Cancer
3 विचारों
administrator
07/03/23
Panelists Adam M. Brufsky, MD, PhD; José Baselga, MD, PhD; Carlos L. Arteaga, MD; Debu Tripathy, MD; and Denise A. Yardley, MD, discuss the potential for use of PI3K inhibitors buparlisib, alpelisib, and taselisib and their anticipation of data coming in the near future for breast cancer.
और दिखाओ
फेसबुक टिप्पणियाँ
कोई टिप्पणी नहीं मिली